NAD+ biosynthesis and signaling as an emerging area in medicinal chemistry

Current Topics in Medicinal Chemistry

Volumn 13, Issue 23, 2013, Pages 2905-2906

  Nencioni, Alessio ^a   Bruzzone, Santina ^a   Del Rio, Alberto ^b,c  

^a UNIVERSITY OF GENOA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; CD38 ANTIGEN; DAPORINAD; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE; OXYTOCIN; SIRTUIN 1; SIRTUIN 3; SIRTUIN 6;

ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CIRCADIAN RHYTHM; DNA REPAIR; EDITORIAL; GENOMIC INSTABILITY; HOMEOSTASIS; HUMAN; IMMUNITY; NEUROPROTECTION; NUCLEOTIDE METABOLISM; SIGNAL TRANSDUCTION;

EID: 84889044344     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660205     Document Type: Editorial

References (22)

1. Yang, H.; Lavu, S.; Sinclair, D. A. Nampt/PBEF/Visfatin: a Regulator of Mammalian Health and Longevity? Exp. Gerontol., 2006, 41, 718-26.
2. Hasmann, M.; Schemainda, I. FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Res., 2003, 63, 7436-42.
3. Lord, C. J.; Ashworth, A. Targeted Therapy for Cancer Using PARP Inhibitors. Curr. Opin. Pharmacol., 2008, 8, 363-9.
4. Dani, N.; Jorge Moura Barbosa, A.; Del Rio, A.; Di Girolamo, M. ADP-Ribosylated Proteins as Old and New Drug Targets for Anticancer Therapy: The Example of ARF6. Curr. Pharm. Des., 2013, 19, 624-633.
5. Mao, Z.; Hine, C.; Tian, X.; Van Meter, M.; Au, M.; Vaidya, A.; Seluanov, A.; Gorbunova, V. SIRT6 Promotes DNA Repair Under Stress by Activating PARP1. Science, 2011, 332, 1443-6.
6. Malavasi, F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A. L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Evolution and Function of the ADP Ribosyl cyclase/CD38 Gene Family in Physiology and Pathology. Physiol. Rev., 2008, 88, 841-86.
7. Finkel, T.; Deng, C.-X.; Mostoslavsky, R. Recent Progress in the Biology and Physiology of Sirtuins. Nature, 2009, 460, 587-91.
8. Langley, B.; Sauve, A. Sirtuin Deacetylases as Therapeutic Targets in the Nervous System. Neurotherapeutics, 2013, 10, 605-20.
9. Nakahata, Y.; Kaluzova, M.; Grimaldi, B.; Sahar, S.; Hirayama, J.; Chen, D.; Guarente, L. P.; Sassone-Corsi, P. The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and Circadian Control. Cell, 2008, 134, 329-40.
10. Montecucco, F.; Cea, M.; Bauer, I.; Soncini, D.; Caffa, I.; Lasigliè, D.; Nahimana, A.; Uccelli, A.; Bruzzone, S.; Nencioni, A. Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience. Curr. Drug Targets, 2013, 14, 637-43.
11. Bruzzone, S.; Fruscione, F.; Morando, S.; Ferrando, T.; Poggi, A.; Garuti, A.; D'Urso, A.; Selmo, M.; Benvenuto, F.; Cea, M.; Zoppoli, G.; Moran, E.; Soncini, D.; Ballestrero, A.; Sordat, B.; Patrone, F.; Mostoslavsky, R.; Uccelli, A.; Nencioni, A. Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS One, 2009, 4, e7897.
12. Busso, N.; Karababa, M.; Nobile, M.; Rolaz, A.; Van Gool, F.; Galli, M.; Leo, O.; So, A.; De Smedt, T. Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase/visfatin Enzymatic Activity Identifies a New Inflammatory Pathway Linked to NAD. PLoS One, 2008, 3, e2267.
13. Rongvaux, A.; Shea, R. J.; Mulks, M. H.; Gigot, D.; Urbain, J.; Leo, O.; Andris, F. Pre-B-Cell Colony-Enhancing Factor, Whose Expression Is up-Regulated in Activated Lymphocytes, Is a Nicotinamide Phosphoribosyltransferase, a Cytosolic Enzyme Involved in NAD Biosynthesis. Eur. J. Immunol., 2002, 32, 3225-34.
14. Dölle, C.; Hvidsten Skoge, R.; VanLinden, M. R.; Ziegler, M. NAD Biosynthesis in Humans-Enzymes, Metabolites and Therapeutic Aspects. Curr. Top. Med. Chem., 2013, 13, 2907-917.
15. Di Stefano, G.; Manerba, M.; Vettraino, M. NAD Metabolism and Functions: a Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases. Curr. Top. Med. Chem., 2013, 13, 2918-929.
16. Montecucco, F.; Cea, M.; Cagnetta, A.; Damonte, P.; Nahimana, A.; Ballestrero, A.; Del Rio, A.; Bruzzone, S.; Nencioni, A. Nicotinamide Phosphoribosyltransferase as a Target in Inflammation-Related Disorders. Curr. Top. Med. Chem., 2013, 13, 2930-938.
17. Liscio, P.; Camaioni, E.; Carotti, A.; Pellicciari, R.; Macchiarulo, A. From Polypharmacology to Target Specificity: The Case of PARP Inhibitors. Curr. Top. Med. Chem., 2013, 13, 2939-954.
18. Vaisitti, T.; Audrito, V.; Serra, S.; Bologna, C.; Arruga, F.; Brusa, D.; Buonincontri, R.; Branimir, G.; Deaglio, S. Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic Target in Chronic Lymphocytic Leukemia. Curr. Top. Med. Chem., 2013, 13, 2955-964.
19. Salmina, A. B.; Lopatina, O.; Kuvacheva, N. V; Higashida, H. Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion. Curr. Top. Med. Chem., 2013, 13, 2965-977.
20. Guse, A. H.; Ernst, I. M. A.; Fliegert, R. NAADP Signaling Revisited. Curr. Top. Med. Chem., 2013, 13, 2978-990.
21. Etchegaray, J.-P.; Zhong, L.; Mostoslavsky, R. The Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease. Curr. Top. Med. Chem., 2013, 13, 2991-3000.
22. Di Girolamo, M.; Fabrizio, G.; Scarpa, E. S.; Di Paola, S. NAD+-Dependent Enzymes Located at the Endoplasmic Reticulum. Curr. Top. Med. Chem., 2013, 13, 3001-3010.